Bimagrumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Bimagrumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 2
Highest phase
19
Registered trials
18
Result records
2
Matched deals
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Bimagrumab can convert its Bispecific antibody profile and ACVR2A x ACVR2B biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Bimagrumab (query alias: bimagrumab) |
|---|---|
| Modality / target | Bispecific antibody; ACVR2A x ACVR2B; ACVR2A modulators, ACVR2B modulators |
| Highest global status | Phase 2 |
| Originator | MorphoSys AG |
| Active developers | Eli Lilly & Co. |
The MCP disease footprint includes Obesity. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06643728 | Phase 2 | Active, not recruiting | 252 | Percent Change from Baseline in Body Weight |
| NCT06901349 | Phase 2 | Withdrawn | Not disclosed | Percent Change from Baseline in Body Weight |
| NCT06890611 | Phase 1 | Completed | 125 | Pharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test Material |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
Phase 2; n=507; evaluation: Positive. Reported fields: Body weight(At week 48,the least squares mean) = was −6.0 kg to −9.3 kg (bimagrumab), −9.8 kg to −14.2 kg (semaglutide) and −12.7 kg to −17.8 kg (combination) versus −3.3 kg (placebo) (all P < 0.001 versus placebo, except bimagrumab 10 mg/kg. kg ; Body weight(At week 48,the least squares mean) = was −6.0 kg to −9.3 kg (bimagrumab), −9.8 kg to −14.2 kg (semaglutide) and −12.7 kg to −17.8 kg (combination) versus −3.3 kg (placebo) (all P < 0.001 versus placebo, except bimagrumab 10 mg/kg. kg ; Body weight(At week 48,the least squares mean) = was −6.0 kg to −9.3 kg (bimagrumab), −9.8 kg to −14.2 kg (semaglutide) and −12.7 kg to −17.8 kg (combination) versus −3.3 kg (placebo) (all P < 0.001 versus placebo, except bimagrumab 10 mg/kg. kg
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
Phase 2; n=507; evaluation: not stated. Reported fields: Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -13.86 kilogram (kg) (Standard Error, 1.29); Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -3.31 kilogram (kg) (Standard Error, 1.39); Change From Baseline in Body Weight at Week 48(Least Squares Mean): LS Mean Change difference = -14.5(95% CI, -18.0 to -11.0), P-Value = <0.001; LS Mean Change difference = -10.5(95% CI, -14.0 to -7.09), P-Value = <0.001; LS Mean Change difference = -11.0(95% CI, -14.4 to -7.55), P-Value = <0.001; LS Mean Change difference = -9.41(95% CI, -12.9 to -5.93), P-Value = <.001; LS Mean Change difference = -10.9(95% CI, -14.4 to -7.46), P-Value = <0.001; LS Mean Change difference = -6.45(95% CI, -9.96 to -2.94), P-Value = <0.001; LS Mean Change difference = -5.94(95% CI, -9.47 to -2.41), P-Value = <0.001; LS Mean Change difference = -2.68(95% CI, -6.18 to 0.82), P-Value = 0.133
New GLP-1 Therapies Enhance Quality of Weight Loss by Improving Muscle Preservation
Phase 2; n=507; evaluation: Positive. Reported fields: Body weight = -10.8 % ; Body weight = -22.1 % ; Body weight = -15.7 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Bimagrumab addresses Obesity. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-07-14 | Lilly Completes Acquisition of Versanis Bio | Phase 2 | US$1,925.0M stated total |
| 2021-08-31 | Versanis Bio snags $70M for a ditched Novartis muscle drug, with a little help from its old CEO Jimenez | Phase 2/3 | US$70.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
